Recent dismissals at the U.S. Food and Drug Administration have extended to employees reviewing Neuralink’s brain implant efforts, sparking concerns about the potential delay in processing medical device applications. According to knowledgeable sources, approximately 20 individuals from the FDA’s neurological medicine devices division were let go in broader government cuts.
About the Author
